TY - BOOK AU - Carpenter,Daniel P. TI - Reputation and power: organizational image and pharmaceutical regulation at the FDA T2 - Princeton studies in American politics : historical, international, and comparative perspectives SN - 9781400835119 AV - RA401.A3 C37 2010eb U1 - 362.17/82 22 PY - 2010/// CY - Princeton PB - Princeton University Press KW - United States KW - Food and Drug Administration KW - fast KW - Pharmaceutical policy KW - Drugs KW - Research KW - Médicaments KW - Politique gouvernementale KW - États-Unis KW - Recherche KW - MEDICAL KW - Allied Health Services KW - General KW - bisacsh KW - Pharmacology KW - Electronic books N1 - Includes bibliographical references and index; Introduction; The gatekeeper --; Reputation and regulatory power --; Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath --; The ambiguous emergence of American pharmaceutical regulation, 1944-1961 --; Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 --; Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 --; Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 --; Reputation and the organizational politics of new drug review --; The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite --; The other side of the gate : reputation, power, and post-market regulation --; The détenté of firm and regulator --; American pharmaceutical regulations in international context : audiences, comparisons, and dependencies --; Conclusion; A reputation in brief N2 - The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr UR - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=329845 ER -